[go: up one dir, main page]

MX2019001696A - Combinacion de agonistas inversos de receptor de histamina-3 con inhibidores de acetilcolinesterasa. - Google Patents

Combinacion de agonistas inversos de receptor de histamina-3 con inhibidores de acetilcolinesterasa.

Info

Publication number
MX2019001696A
MX2019001696A MX2019001696A MX2019001696A MX2019001696A MX 2019001696 A MX2019001696 A MX 2019001696A MX 2019001696 A MX2019001696 A MX 2019001696A MX 2019001696 A MX2019001696 A MX 2019001696A MX 2019001696 A MX2019001696 A MX 2019001696A
Authority
MX
Mexico
Prior art keywords
combination
histamine
acetylcholinesterase inhibitors
inverse agonists
receptor inverse
Prior art date
Application number
MX2019001696A
Other languages
English (en)
Other versions
MX374114B (es
Inventor
Jasti Venkateswarlu
Nirogi Ramakrishna
Karbhari Shinde Anil
Bhyrapuneni Gopinadh
Rasheed Mohammed Abdul
Jayarajan Pradeed
Original Assignee
Suven Life Sciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Suven Life Sciences Ltd filed Critical Suven Life Sciences Ltd
Publication of MX2019001696A publication Critical patent/MX2019001696A/es
Publication of MX374114B publication Critical patent/MX374114B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se refiere a la combinación de agonista inverso del receptor de histamina 3 e inhibidor de acetilcolinesterasa. También, la presente invención proporciona un agonista inverso del receptor de histamina 3 (H3R) o su sal o sales farmacéuticamente aceptables en combinación o como auxiliar de inhibidores de acetilcolinesterasa y su uso en el tratamiento de trastornos cognitivos. La presente invención también proporciona la composición farmacéutica que contiene dicha combinación.
MX2019001696A 2016-08-18 2017-08-14 Combinación de agonistas inversos de receptor de histamina-3 con inhibidores de acetilcolinesterasa. MX374114B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN201641028166 2016-08-18
PCT/IB2017/054938 WO2018033847A1 (en) 2016-08-18 2017-08-14 Combination of histamine-3 receptor inverse agonists with acetylcholinesterase inhibitors

Publications (2)

Publication Number Publication Date
MX2019001696A true MX2019001696A (es) 2019-07-04
MX374114B MX374114B (es) 2025-03-04

Family

ID=59887325

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019001696A MX374114B (es) 2016-08-18 2017-08-14 Combinación de agonistas inversos de receptor de histamina-3 con inhibidores de acetilcolinesterasa.

Country Status (28)

Country Link
US (1) US10603323B2 (es)
EP (1) EP3500253B1 (es)
JP (1) JP6734470B2 (es)
KR (1) KR102039585B1 (es)
CN (1) CN109640975B (es)
AU (1) AU2017313427B2 (es)
CA (1) CA3033039C (es)
CY (1) CY1123238T1 (es)
DK (1) DK3500253T3 (es)
EA (1) EA032957B1 (es)
ES (1) ES2810983T3 (es)
HR (1) HRP20201262T1 (es)
HU (1) HUE052003T2 (es)
IL (1) IL264406B (es)
LT (1) LT3500253T (es)
MA (1) MA45990B1 (es)
MD (1) MD3500253T2 (es)
ME (1) ME03812B (es)
MX (1) MX374114B (es)
NZ (1) NZ750150A (es)
PL (1) PL3500253T3 (es)
PT (1) PT3500253T (es)
RS (1) RS60669B1 (es)
SG (1) SG11201900681SA (es)
SI (1) SI3500253T1 (es)
SM (1) SMT202000435T1 (es)
WO (1) WO2018033847A1 (es)
ZA (1) ZA201900467B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA52850B1 (fr) * 2018-05-31 2025-03-28 Suven Life Sciences Limited Méthode de traitement avec un agoniste inverse du récepteur de l'histamine-3

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2764808A1 (en) * 2009-06-10 2010-12-16 Sunovion Pharmaceuticals Inc. Histamine h3 inverse agonists and antagonists and methods of use thereof
WO2012114348A1 (en) * 2011-02-23 2012-08-30 Suven Life Sciences Limited Novel compounds as histamine h3 receptor ligands
FR2974729B1 (fr) * 2011-05-02 2013-04-19 Servier Lab Nouvelle association entre le 4-{3-[cis-hexahydrocyclopenta[c]pyrrol-2(1h)-yl]propoxy}benzamide et un inhibiteur de l'acetylcholinesterase et les compositions pharmaceutiques qui la contiennent
HUP1300139A2 (en) * 2013-03-06 2014-09-29 Richter Gedeon Nyrt Phenoxypiperidine h3 antagonists
CN105764510A (zh) 2013-09-09 2016-07-13 赛诺菲 H3受体拮抗剂与胆碱酶抑制剂组合用于阿尔茨海默氏病治疗中的用途

Also Published As

Publication number Publication date
BR112019002645A2 (pt) 2019-05-28
EA201990480A1 (ru) 2019-05-31
RS60669B1 (sr) 2020-09-30
DK3500253T3 (da) 2020-08-17
CA3033039A1 (en) 2018-02-22
ES2810983T3 (es) 2021-03-10
US10603323B2 (en) 2020-03-31
AU2017313427A1 (en) 2019-02-28
KR20190031330A (ko) 2019-03-25
HUE052003T2 (hu) 2021-04-28
WO2018033847A1 (en) 2018-02-22
SG11201900681SA (en) 2019-02-27
CN109640975B (zh) 2020-10-20
PT3500253T (pt) 2020-08-05
JP6734470B2 (ja) 2020-08-05
HRP20201262T1 (hr) 2020-12-11
IL264406A (en) 2019-02-28
IL264406B (en) 2019-07-31
ME03812B (me) 2021-04-20
CY1123238T1 (el) 2021-10-29
CN109640975A (zh) 2019-04-16
MA45990A (fr) 2019-06-26
JP2019524794A (ja) 2019-09-05
LT3500253T (lt) 2020-08-25
AU2017313427B2 (en) 2020-01-30
SMT202000435T1 (it) 2020-09-10
PL3500253T3 (pl) 2020-11-16
ZA201900467B (en) 2020-06-24
MA45990B1 (fr) 2020-08-31
EP3500253B1 (en) 2020-06-24
NZ750150A (en) 2020-08-28
MX374114B (es) 2025-03-04
SI3500253T1 (sl) 2020-10-30
US20190160075A1 (en) 2019-05-30
KR102039585B1 (ko) 2019-11-01
EP3500253A1 (en) 2019-06-26
MD3500253T2 (ro) 2020-09-30
EA032957B1 (ru) 2019-08-30
CA3033039C (en) 2020-06-23

Similar Documents

Publication Publication Date Title
CL2017000469A1 (es) Derivados de tetrahidronaftaleno que inhiben la proteina mcl-1
UY38221A (es) Inhibidores de proteínas ras con g12c mutantes
UY38001A (es) Compuestos que inhiben las proteínas ras mutantes g12c
CL2019002777A1 (es) Compuestos que inhiben la proteína mcl-1.
MX2022012313A (es) Oxisteroles y metodos de uso de los mismos.
MX2018008052A (es) Inhibidores de desmetilasa especifica de lisina 1 (lsd1).
CL2017000902A1 (es) Dihidropirrolopiridinas inhibidoras de ror-gamma
MX2016012097A (es) Derivados de bencimidazol como inhibidores de tirosina cinasa erbb para el tratamiento del cáncer.
SV2017005405A (es) Compuestos y composiciones como inhibidores de quinasa raf
SV2018005680A (es) Compuestos de imidazo [4,5-c] quinolin- 2-ona y su uso en el tratamiento del cancer
CR20190517A (es) Análogos de benzoazepina como agentes inhibidores de la tirosina cinasa de bruton
UY36003A (es) Derivados de amida, procesos de preparación y composiciones, útiles en afecciones asociadas con el receptor sub-tipo 1 de orexina.
MX2018004664A (es) Antagonistas de ep4.
UY36875A (es) Composiciones inhibidoras de bromodominios para el tratamiento de diversas enfermedades
MX388378B (es) Compuestos de aza-indazol para usar en lesiones de tendones y/o ligamentos.
DOP2015000214A (es) Nuevos compuestos inhibidores de la fosfodiesterasa del tipo 10a
MX2016010524A (es) Derivados de piridazina para uso en la prevencion o tratamiento de trastorno ataxico.
SV2017005354A (es) Derivados de quinolizinona como inhibidores de pi3k
CO2022000266A2 (es) Inhibidores de enzimas
AR113958A1 (es) Macrociclos a como inhibidores de pde1
CR20180368A (es) Compuestos de dihidroquinolinsulfonamida de alquilo
UY37729A (es) NUEVOS COMPUESTOS QUE INHIBEN LA ACTIVIDAD DE Nav1.7
AR099766A1 (es) Inhibidores de la quinasa asociada al adaptador 1, composiciones que los comprenden y métodos para utilizarlos
BR112018073419A2 (pt) combinação, uso da combinação, método para o tratamento, composto, método para o tratamento de doença de alzheimer e composição farmacêutica
MX380547B (es) Composición que comprende un inhibidor de fgfr1/kdr micronizado y el uso del mismo en el tratamiento de tumores neuroendocrinos.

Legal Events

Date Code Title Description
FG Grant or registration